Integrated BioPharma Q4 rev $14.2M (+11.8%); net loss $0.2M on tax; FY net income $808k

INTEGRATED BIOPHARMA INC

Q4 revenue $14.2M vs $12.7M (+11.8%); operating income $589k vs $402k.
Q4 net loss $178k ($0.01 loss per share) vs net income $268k ($0.01 EPS) prior year; tax expense $773k.
FY2025 revenue $54.4M (+8.0%); net income $808k ($0.03 diluted EPS) vs $112k ($0.00 EPS) prior year.
FY operating income $2.0M vs $251k; selling and administrative expenses flat.
Weighted average diluted shares for FY 31.2M vs 30.9M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.